Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Sosei Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Sosei Group Corp, Medical Devices Deals, 2012 to YTD 2018 11
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Sosei Group Corp, Pharmaceuticals & Healthcare, Deal Details 14
Venture Financing 14
Heptares Therapeutics Raises US$21 Million In Series B Financing 14
Partnerships 15
Heptares Therapeutics Enters into Research Agreement with Imperial College London 15
Heptares Therapeutics Enters into Research Agreement with Juntendo University 16
Heptares Therapeutics and PeptiDream Enter into Agreement 17
Heptares Therapeutics Enters into Research Agreement with New York University School of Medicine 18
Heptares Therapeutics Enters into Research Agreement with University of Cambridge 19
Pluristem Therapeutics to Partner with Sosei Corporate Venture Capital 20
Jitsubo Enters into Agreement with Heptares Therapeutics 21
Heptares Therapeutics and leadXpro Enter into Agreement 22
Heptares Therapeutics to Form Partnership with Kymab 23
Heptares Therapeutics Enters into Agreement with Pfizer 24
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 25
Sosei Plans to Enter into Agreement with Novartis 26
Sosei Enters Into Distribution Agreement With Fujifilm Pharma For SO-1105 27
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 28
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 29
Heptares Therapeutics Extends Collaboration with the UK Medical Research 30
ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 31
Licensing Agreements 32
Daiichi Sankyo Enters into Licensing Agreement with Sosei Group 32
Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 33
Allergan Amends Licensing Agreement with Heptares Therapeutics 34
AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 35
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 36
Equity Offering 37
Sosei Group to Raise up to USD199.5 Million in Public Offering of Shares 37
Sosei Group Raises USD33 Million in Private Placement of Shares 38
Sosei Group to Raise USD7 Million in Private Placement of Shares 39
Sosei Group to Raise USD66 Million in Public Offering of Shares 40
Jitsubo to Raise USD1.7 Million in Private Placement 41
Sosei Announces Private Placement Of Preference Shares For US$3.9 Million 42
Asset Transactions 43
Beijing Tide Pharma Acquires Rights To SD118 From Sosei 43
Acquisition 44
Formosa Labs Acquires Activus Pharma from Sosei Group 44
Sosei to Acquire 25.6% Stake in MiNA Therapeutics for USD45.2 Million 45
Heptares Therapeutics Acquires G7 Therapeutics for USD11.8 Million 47
Sosei Acquires Heptares Therapeutics for USD400 Million 48
Sosei Acquires Stake in Jitsubo for USDUSD1.8 Million 49
Sosei Group Corp – Key Competitors 50
Sosei Group Corp – Key Employees 51
Sosei Group Corp – Locations And Subsidiaries 52
Head Office 52
Other Locations & Subsidiaries 52
Recent Developments 54
Financial Announcements 54
Nov 09, 2017: Sosei Group: Consolidated Financial Results for the Second Period FY2017 (IFRS) 54
Corporate Communications 58
Jun 04, 2018: Sosei Announces Appointment of Chris Cargill as Interim CFO 58
Jan 19, 2018: Sosei Group Announces Resignation Of Fiona Marshall As Chief Scientific Officer 59
Jan 19, 2018: Changes in Executive Management at Sosei 60
Product News 61
May 31, 2017: Sosei Subsidiary Heptares Solves First Full-length Structure of GLP-1 Receptor Bound to Peptide Agonist 61
Other Significant Developments 62
Feb 02, 2018: Sosei Announces Restatements of Previously Issued Quarterly and Full Year Accounts 62
Jan 26, 2017: Achievement of sales milestone for COPD products 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64
Sosei Group Corp, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Sosei Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Sosei Group Corp, Deals By Therapy Area, 2012 to YTD 2018 10
Sosei Group Corp, Medical Devices Deals, 2012 to YTD 2018 11
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Heptares Therapeutics Raises US$21 Million In Series B Financing 14
Heptares Therapeutics Enters into Research Agreement with Imperial College London 15
Heptares Therapeutics Enters into Research Agreement with Juntendo University 16
Heptares Therapeutics and PeptiDream Enter into Agreement 17
Heptares Therapeutics Enters into Research Agreement with New York University School of Medicine 18
Heptares Therapeutics Enters into Research Agreement with University of Cambridge 19
Pluristem Therapeutics to Partner with Sosei Corporate Venture Capital 20
Jitsubo Enters into Agreement with Heptares Therapeutics 21
Heptares Therapeutics and leadXpro Enter into Agreement 22
Heptares Therapeutics to Form Partnership with Kymab 23
Heptares Therapeutics Enters into Agreement with Pfizer 24
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 25
Sosei Plans to Enter into Agreement with Novartis 26
Sosei Enters Into Distribution Agreement With Fujifilm Pharma For SO-1105 27
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 28
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 29
Heptares Therapeutics Extends Collaboration with the UK Medical Research 30
ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 31
Daiichi Sankyo Enters into Licensing Agreement with Sosei Group 32
Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 33
Allergan Amends Licensing Agreement with Heptares Therapeutics 34
AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 35
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 36
Sosei Group to Raise up to USD199.5 Million in Public Offering of Shares 37
Sosei Group Raises USD33 Million in Private Placement of Shares 38
Sosei Group to Raise USD7 Million in Private Placement of Shares 39
Sosei Group to Raise USD66 Million in Public Offering of Shares 40
Jitsubo to Raise USD1.7 Million in Private Placement 41
Sosei Announces Private Placement Of Preference Shares For US$3.9 Million 42
Beijing Tide Pharma Acquires Rights To SD118 From Sosei 43
Formosa Labs Acquires Activus Pharma from Sosei Group 44
Sosei to Acquire 25.6% Stake in MiNA Therapeutics for USD45.2 Million 45
Heptares Therapeutics Acquires G7 Therapeutics for USD11.8 Million 47
Sosei Acquires Heptares Therapeutics for USD400 Million 48
Sosei Acquires Stake in Jitsubo for USDUSD1.8 Million 49
Sosei Group Corp, Key Competitors 50
Sosei Group Corp, Key Employees 51
Sosei Group Corp, Other Locations 52
Sosei Group Corp, Subsidiaries 52
List of Figures
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Sosei Group Corp, Medical Devices Deals, 2012 to YTD 2018 11